Subscribe Now
Forgot Password?

Weekly News, Analysis, and Commentary

Legal & Regulatory Feature

TheraCell’s DBF / Courtesy of TheraCell

TheraCell: Second Patent for DBF

Elizabeth Hofheinz, M.P.H., M.Ed. • Fri, March 17th, 2017

Print this article

TheraCell Inc., headquartered in Los Angeles, has announced the second patent for its demineralized bone fiber (DBF) by the U.S. Patent and Trademark Office. As indicated in the March 9, 2017 news release, “TheraCell’s DBF technology is incorporated into two innovative demineralized cortical fiber allograft, AlloFuse Cortical Fibers and AlloFuse Fiber Boat, commercialized by AlloSource….”

“This second patent shows TheraCell’s dedication to advancing the science behind demineralized bone fiber allografts,” said AlloSource Chief Commerical Officer Kerr Holbrook. “Including this patented technology in AlloSource’s product portfolio is important to providing our surgeon customers solutions to help patients in need, while continuing to fully honor our tissue donors.”

Andy Carter, Ph.D. is chief technology officer at TheraCell. He told OTW, “Our process is highly efficient and yields uniform fibers that are both osteoinductive and osteoconductive, and the ‘cotton wool’ like properties means that there are no additives so the implant is pure demineralized bone. The DBF can be treated like textile fibers and processed to make shapes such as the Fiber Boat product. This provides ease of handling and use for spine surgeons doing posterolateral fusions.”

“Studies have shown good bone healing in a range of animal models and the product is now commercially available through AlloSource.”

Send to a Friend

The article link will be sent to the email address you provide

Your Name (required)

Your Email (required)

Friend's Email (required)


Leave a Reply


Email Address (will not be published)